If this research reaches its sci-fi endpoint, your oncologist does not just say, "There is a tumor." They say, "This thing is growing fast, dodging immune patrol, building suspicious plumbing, flirting with metastasis, and generally behaving like a startup with no adult supervision." Dial that back to reality, and Grimm and colleagues are asking a very practical question: can medical imaging show us the hallmarks of cancer without needing to repeatedly poke the tumor with needles?

So here is the thing, cancer is not one trick. It is a whole bag of bad decisions made by cells that stopped reading the employee handbook. Hanahan and Weinberg's famous "hallmarks of cancer" framework gave researchers a way to organize the chaos: uncontrolled growth, evading cell death, creating blood vessels, invading other tissues, rewiring metabolism, hiding from the immune system, and more. It is basically a checklist for how normal biology becomes a tiny criminal enterprise.

The new Nature Reviews Cancer paper, Imaging the hallmarks of cancer, argues that scans can do more than locate tumors. They can help measure what tumors are doing.

Scans That Snitch

Traditional imaging often answers location questions: Where is the tumor? How big is it? Did it shrink after therapy? Useful, yes. But biology is sneaky. A tumor can look similar in size while changing its metabolism, immune environment, oxygen levels, or growth behavior. That is like judging a restaurant only by its front door while the kitchen is on fire.

This review walks through imaging methods that can probe cancer hallmarks directly or indirectly. PET tracers can reveal metabolism or molecular targets. MRI can capture tissue structure, oxygenation, blood flow, and microenvironment clues. CT can expose anatomy and, with the right analysis, patterns of heterogeneity. Some probes target specific molecules. Others infer biology from pathophysiology, which is a fancy way of saying, "We cannot see the villain directly, but we can see the footprints, the broken window, and the suspiciously warm getaway car."

Enter AI, Wearing a Lab Coat Slightly Too Big

This is where it gets interesting. The paper highlights AI-assisted multiparametric image analysis: radiomics, radiogenomics, and deep learning. Radiomics treats images as data mines, extracting textures, shapes, intensities, and spatial patterns that human eyes might miss. Deep learning then tries to learn useful patterns directly from the scans, because apparently even medical images now need a neural network whisperer.

Radiogenomics adds another layer: connecting image patterns with gene expression, mutations, or molecular pathways. Recent work backs up the direction of travel. A 2024 systematic review of CT radiogenomics in lung cancer found that combined imaging-plus-genomics models often outperformed either alone, though studies were still mostly retrospective and small. Translation: promising, but not yet the kind of thing you want making solo clinical decisions while everyone else goes for coffee.

Meanwhile, newer hallmark-focused AI tools are popping up. OncoMark, published in 2025, uses neural multi-task learning to estimate ten cancer hallmark activities from transcriptomic data. That is not imaging, but it points to the same dream: summarize messy tumor biology into measurable signals clinicians can actually use.

Why This Matters At The Bedside

Let me unpack that. Cancer treatment is increasingly aimed at specific biological behaviors: block a growth signal, starve a tumor's blood supply, wake up the immune system, deliver radiopharmaceuticals to a target. But if the tumor changes tactics, clinicians need a way to notice. Repeated biopsies are invasive, geographically limited, and not exactly anyone's preferred Tuesday activity.

Imaging can be longitudinal, whole-body, and quantitative. That means doctors could track whether therapy is hitting the intended hallmark, whether resistant regions are emerging, or whether different parts of the tumor are playing different biological games. Tumor heterogeneity is the real headache here. One lesion may be immune-cold, another metabolically hyperactive, another quietly preparing its villain monologue.

There is a natural link to everyday image AI too. Tools like combb2.io use enhancement ideas such as denoising and sharpening to make images more readable, though clinical imaging demands a much higher bar: validation, calibration, regulation, and zero tolerance for "the pixels looked prettier, trust me."

The Catch, Because Biology Always Sends A Bill

The hard part is proving these signals mean what we think they mean. AI models can learn scanner quirks, hospital workflows, reconstruction settings, or hidden bias instead of tumor biology. Radiomics features can wobble when acquisition protocols change. Deep learning models can perform beautifully in one dataset and then faceplant elsewhere like they forgot their shoes.

The authors' strongest point is not "AI will magically solve cancer imaging." It is more grounded: if we want hallmark-targeted therapies, we need hallmark-aware biomarkers. Imaging is one of the few tools that can repeatedly watch cancer across the body without turning every follow-up into a biopsy scavenger hunt.

If reproducible and expanded, this line of work could shift cancer imaging from a measuring tape to a biological dashboard. Not perfect. Not mystical. Just more informative. And in oncology, more informative can mean better treatment selection, earlier course correction, and fewer therapies fired blindly into the fog.

References

1. Grimm J, Kiessling F, Brindle KM, et al. Imaging the hallmarks of cancer. Nature Reviews Cancer. 2026. DOI: 10.1038/s41568-026-00950-y

2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000. DOI: 10.1016/S0092-8674(00)81683-9

3. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discovery. 2022. DOI: 10.1158/2159-8290.CD-21-1059

4. Swanton C, Bernard E, Abbosh C, et al. Embracing cancer complexity: Hallmarks of systemic disease. Cell. 2024. DOI: 10.1016/j.cell.2024.02.009

5. Jiang Y, Gao C, Shao Y, et al. The prognostic value of radiogenomics using CT in patients with lung cancer: a systematic review. Insights into Imaging. 2024. DOI: 10.1186/s13244-024-01831-4

6. Priyadarshi S, Mazumder C, Neekhra B, et al. OncoMark: a high-throughput neural multi-task learning framework for comprehensive cancer hallmark quantification. Communications Biology. 2025. DOI: 10.1038/s42003-025-08727-z

Disclaimer: This blog post is a simplified summary of published research for educational purposes. The accompanying illustration is artistic and does not depict actual model architectures, data, or experimental results. Always refer to the original paper for technical details.